

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1.-35. (Canceled)

36. (Currently Amended) A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution and precipitated vinorelbine, wherein the precipitated vinorelbine in said liposome is at least 50% of the total vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio in the range of about 75/25 mol%/mol% sphingomyelin/cholesterol to about 30/50 mol%/mol% sphingomyelin/cholesterol, and wherein the ratio of said vinorelbine to lipid is 0.4 ± 0.5 :1 (w/w).

37.-42. (Canceled)

43. (Previously Presented) The liposomal formulation of claim 36, wherein said liposome comprises sphingomyelin and cholesterol in a 55:45 molar ratio.

44.-66. (Canceled)

67. (Previously Presented) The liposomal formulation of claim 36, wherein said liposome comprises sphingomyelin and cholesterol in a 50:50 molar ratio.

68. (Currently Amended) The liposomal formulation of claim ~~66~~ 36, wherein the ratio of said vinorelbine to said lipid is about 0.3:1 (w/w).

69.-70. (Canceled)

71. (New) A liposomal formulation, said liposomal formulation comprising a liposome having vinorelbine in solution and precipitated vinorelbine, wherein the precipitated vinorelbine in said liposome is at least 50% of the total vinorelbine, wherein said liposome comprises sphingomyelin and cholesterol at a ratio of about 55/45 mol%/mol% sphingomyelin/cholesterol, and wherein the ratio of said vinorelbine to lipid is about 0.3:1 (w/w).